Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 399 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Testosterone Clear all

Conditions: Gonadotropin Deficiency
Interventions: Testosterone 1% Gel, Acyline, Dutasteride, Ketoconazole, HCG, placebo dutasteride, placebo ketoconazole; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 55 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions: Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitors (ARPIs); Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Healthy Males
Interventions: Acyline, Testosterone gel, ketoconazole 400, Ketoconazole 800, Dutasteride, Anastrozole, Placebo ketoconazole; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate, Enzalutamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Alcohol Drinking, Weight Loss, Adiposity, Obesity, Visceral Obesity
Interventions: Alcohol, No Alcohol; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Sexual Function, Cognitive Functions, Testosterone
Interventions: Essential Elements T-Hero Platinum, Placebo; Dietary Supplement
Lead sponsor: Scale Media Inc; Industry
Eligibility: 30 Years to 65 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Hypogonadism
Interventions: AndroGel (Transdermal Testosterone Gel); Drug
Lead sponsor: Lamm, Steven, M.D.; Individual
Eligibility: 21 Years to 59 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Erectile Dysfunction, Sexual Dysfunction
Interventions: Natesto Nasal Product, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 64 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Arthroplasty, Replacement, Hip
Interventions: Testosterone Therapy, No Testosterone Therapy; Drug · Other
Lead sponsor: American Hip Institute; Other
Eligibility: 50 Years and older · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Des Plaines, Illinois

Conditions: Known Androgen Deficiency
Interventions: Not listed
Lead sponsor: Saliva Biomarkers, Inc.; Industry
Eligibility: 20 Years to 65 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Hypogonadism
Interventions: Not listed
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 425 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypogonadism, Cardiovascular Diseases
Interventions: AndroGel®, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 5,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 379
States / cities: Alabaster, Alabama • Birmingham, Alabama • Decatur, Alabama + 262 more

Conditions: Erectile Dysfunction
Interventions: LY2452473, Tadalafil, LY900010; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Erectile Dysfunction, Testosterone Deficiency, Diabetes
Interventions: Sildenafil citrate (open label), Testosterone gel, Placebo gel; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metabolic Syndrome, Hypogonadism
Interventions: Testosterone gel, Placebo for testosterone gel; Radiation · Drug
Lead sponsor: McGuire Research Institute; Other
Eligibility: 20 Years to 65 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Bladder Cancer, Low Testosterone Levels
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Healthy, Osteoporosis, Premature Ovarian Failure
Interventions: TMTDS; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 32 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Male Hypogonadism
Interventions: Testosterone Cypionate 75 mg, Testosterone cypionate 50 mg, Testosterone cypionate 100 mg; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Santa Monica, California • DeLand, Florida • Miami Lakes, Florida + 7 more

Conditions: Stress Urinary Incontinence
Interventions: Testosterone patch, Placebo; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Prostate Adenocarcinoma, Progressive Disease, Prostate Carcinoma Metastatic in the Bone, Prostate Carcinoma Metastatic in the Soft Tissue, PSA Progression, Stage IVB Prostate Cancer AJCC v8, Testosterone Less Than 50 ng/dL
Interventions: Recombinant EphB4-HSA Fusion Protein; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Los Angeles, California • Chicago, Illinois

Conditions: Low Testosterone Levels
Interventions: Qualia Testosterone+, Placebo; Dietary Supplement · Other
Lead sponsor: Qualia Life Sciences; Industry
Eligibility: 28 Years to 65 Years · Male only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Hypogonadism, Male
Interventions: Vogelxo; Drug
Lead sponsor: Upsher-Smith Laboratories; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Anaheim, California • Miami, Florida + 3 more

Conditions: Polycystic Ovary Syndrome
Interventions: Flutamide, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Aging, Frail Elderly, Rehabilitation
Interventions: Testosterone supplement; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 65 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Richmond, Virginia

Search by objective public record fields.

ITT-5 Mechanisms of Spermatogenesis in Man

Testosterone-Informed De-Escalation in Metastatic Prostate Cancer (TIDE PC)

ITT4 Intratesticular Hormonal Milieu in Man (ITT4)

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

The Effects of Alcohol Consumption on Central Adiposity

A Clinical Trial to Evaluate the Efficacy of a Men's Supplement in Supporting Testosterone, Improving Cognitive Function, Mood, and Sexual Function

Transdermal Testosterone Gel/Effect on Erection Quality as Measured by DIR

Natesto Testosterone Nasal Gel for Hypogonadal Men

Does Testosterone Therapy Improve Patient-Reported Outcomes in Age-Related Testosterone Deficient Patients Undergoing Total Hip Replacement: A Randomized-Controlled Trial

Comparison of Salivary and Serum Free Testosterone in Normal and Hypogonadal Men

Survey of Testosterone Levels in Male Cancer Patients

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

A Bioavailability Study of LY2452473 and Tadalafil

Effect of Testosterone in Men With Erectile Dysfunction

Effect of Testosterone Replacement on Insulin Resistance

Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer

Hormone Replacement in Young Women With Premature Ovarian Failure

Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism

Testosterone Replacement in Postmenopausal Women With Stress Urinary Incontinence

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Efficacy of Qualia Testosterone+ on Testosterone Levels in Adult Males

Vogelxo(R) ABPM Study in Hypogandal Men

Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome

The Effect of Testosterone Supplementation on Rehabilitation Outcomes